Cwm LLC Sells 683 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Cwm LLC decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 45.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 835 shares of the company’s stock after selling 683 shares during the period. Cwm LLC’s holdings in Medpace were worth $256,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Riverbridge Partners LLC lifted its holdings in shares of Medpace by 7.1% in the 4th quarter. Riverbridge Partners LLC now owns 652,384 shares of the company’s stock valued at $199,975,000 after acquiring an additional 43,197 shares during the last quarter. Invesco Ltd. lifted its stake in Medpace by 67.6% in the third quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock worth $148,159,000 after purchasing an additional 246,775 shares during the last quarter. Wellington Management Group LLP lifted its stake in Medpace by 312.6% in the third quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock worth $102,013,000 after purchasing an additional 319,210 shares during the last quarter. Northern Trust Corp lifted its stake in Medpace by 4.0% in the third quarter. Northern Trust Corp now owns 241,202 shares of the company’s stock worth $58,402,000 after purchasing an additional 9,192 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in Medpace by 55.7% in the third quarter. AQR Capital Management LLC now owns 183,310 shares of the company’s stock worth $44,385,000 after purchasing an additional 65,614 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Insiders Place Their Bets

In other Medpace news, CEO August J. Troendle sold 15,102 shares of Medpace stock in a transaction on Monday, April 29th. The shares were sold at an average price of $400.69, for a total value of $6,051,220.38. Following the transaction, the chief executive officer now directly owns 791,541 shares of the company’s stock, valued at $317,162,563.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Medpace news, major shareholder Medpace Investors, Llc sold 50,000 shares of Medpace stock in a transaction on Friday, February 16th. The shares were sold at an average price of $391.75, for a total value of $19,587,500.00. Following the transaction, the insider now directly owns 5,539,947 shares of the company’s stock, valued at $2,170,274,237.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO August J. Troendle sold 15,102 shares of Medpace stock in a transaction on Monday, April 29th. The stock was sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the completion of the transaction, the chief executive officer now directly owns 791,541 shares in the company, valued at $317,162,563.29. The disclosure for this sale can be found here. Over the last three months, insiders have sold 204,442 shares of company stock valued at $82,702,867. 20.30% of the stock is currently owned by insiders.

Medpace Stock Up 0.4 %

Shares of MEDP stock opened at $392.57 on Friday. The firm has a market cap of $12.16 billion, a price-to-earnings ratio of 40.02, a PEG ratio of 1.98 and a beta of 1.40. The company’s 50 day moving average is $398.08 and its 200 day moving average is $330.45. Medpace Holdings, Inc. has a 52-week low of $197.39 and a 52-week high of $421.00.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The company had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. During the same period last year, the company posted $2.27 earnings per share. Medpace’s revenue was up 17.7% compared to the same quarter last year. Analysts anticipate that Medpace Holdings, Inc. will post 11.23 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on MEDP shares. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and raised their price objective for the stock from $340.00 to $450.00 in a research note on Tuesday, April 23rd. StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a research report on Tuesday, April 23rd. UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and raised their target price for the stock from $282.00 to $452.00 in a research report on Thursday, February 15th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Medpace in a research report on Monday, March 18th. They set a “hold” rating and a $395.00 target price on the stock. Finally, Guggenheim raised their target price on shares of Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $443.00.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.